BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34333645)

  • 1. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group.
    Klein Haneveld MJ; van Treijen MJC; Pieterman CRC; Dekkers OM; van de Ven A; de Herder WW; Zandee WT; Drent ML; Bisschop PH; Havekes B; Vriens MR; Verrijn Stuart AA; Valk GD; van Leeuwaarde RS
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3515-3525. PubMed ID: 34333645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Nell S; Borel Rinkes IHM; Verkooijen HM; Bonsing BA; van Eijck CH; van Goor H; de Kleine RHJ; Kazemier G; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; Vriens MR;
    Ann Surg; 2018 Feb; 267(2):352-356. PubMed ID: 27811505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
    Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
    Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
    Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.
    van Beek DJ; Nell S; Verkooijen HM; Borel Rinkes IHM; Valk GD; ; Vriens MR; ;
    Surgery; 2021 Apr; 169(4):963-973. PubMed ID: 33220975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
    Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
    J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
    Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
    Sadowski SM; Pieterman CRC; Perrier ND; Triponez F; Valk GD
    Endocr Relat Cancer; 2020 Jun; 27(6):R145-R161. PubMed ID: 32229700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
    Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
    van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
    Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?
    Qiu W; Christakis I; Stewart AA; Vodopivec DM; Silva-Figueroa A; Chen H; Woodard TL; Halperin DM; Lee JE; Yao JC; Perrier ND
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):791-797. PubMed ID: 28273369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs.
    van Vliembergen ENM; Eijkelenkamp H; Valk GD; Vriens MR; Meijer GJ; Intven MPW; de Laat JM
    Front Endocrinol (Lausanne); 2023; 14():994370. PubMed ID: 37305036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.
    de Laat JM; Pieterman CR; Weijmans M; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4143-51. PubMed ID: 23956349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
    Marini F; Giusti F; Tonelli F; Brandi ML
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group.
    Nell S; Verkooijen HM; Pieterman CRC; de Herder WW; Hermus AR; Dekkers OM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    Ann Surg; 2018 Jun; 267(6):1155-1160. PubMed ID: 28257328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
    Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
    Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
    Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
    Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing?
    Ramamoorthy B; Nilubol N
    Surg Oncol Clin N Am; 2023 Apr; 32(2):315-325. PubMed ID: 36925188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.